79902-31-1

Usage

Uses

An intermediate used for synthesis of Simvastatin precursor (H941625).

InChI:InChI=1/C25H42O4Si/c1-16-12-18-9-8-17(2)21(24(18)22(26)13-16)11-10-19-14-20(15-23(27)28-19)29-30(6,7)25(3,4)5/h8-9,12,16-17,19-22,24,26H,10-11,13-15H2,1-7H3/t16-,17-,19+,20+,21-,22-,24-/m0/s1

Upstream product

• 75-07-0 acetaldehyde 
• 143746-93-4 6(R)-<2-<8-<(trimethylsilyl)oxy>-2(S),6(S)-dimethyl-1,2,6,8a(R)-tetrahydronaphthyl-1(S)>ethyl>-4(R)-<(tert-butyldimethylsilyl)oxy>-3,4,5,6-tetrahydro-2H-pyranone 
• 151006-15-4 (4R,6R)-4-hydroxy-6-(2-((1S,2S,6R,8S,8aR)-8-hydroxy-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)ethyl)tetrahydro-2H-pyran-2-one 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 75225-51-3 lovastatin acid 
• 132748-10-8 (3R,5R)-3,5-dihydroxy-7-((1S,2S,6R,8S,8aR)-8-hydroxy-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)heptanoic acid 
• 75330-75-5 lovastatin 

Downstream Products

• 79902-45-7 <1S-<1α,3α,7β,8β(2S^*,4S^*)8aβ>>-8-<2-<4-<<(1,1-dimethylethyl)dimethylsilyl>oxy>tetrahydro-6-oxo-2H-pyran-2-yl>ethyl>-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-1-naphthalenyl benzeneacetate 
• 79691-11-5 6(R)-<2-<1,2,6,7,8,8a(R)-Hexahydro-2(S),6(R)-dimethyl-8(S)-<<2(S)-methylbutyryl>oxy>-1(S)-naphtyl>ethyl>-3,4,5,6-tetrahydro-4(R)-<(tert-butyldimethylsilyl)oxy>-2H-pyran-2-one 
• 124879-80-7 6(R)-[2-[8(S)-(2-trifluoromethyl-benzoyloxy)-2(S),6(R) dimethyl 1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-tert-butyl-dimethylsilyloxy-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 1431473-50-5 (4R,6R)-6-[2-((1S,2S,6R,8S,8aR)-8-[((4-ethynylphenyl)carbamoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthyl)ethyl]-4-[(tert-butyldimethylsilyl)oxy]-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 1431473-51-6 (4R,6R)-6-[2-((1S,2S,6R,8S,8aR)-8-[((4-ethynylbenzyl)carbamoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthyl)ethyl]-4-[(tert-butyldimethylsilyl)oxy]-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 1431473-54-9 (4R,6R)-6-[2-((1S,2S,6R,8S,8aR)-8-[((4-{1-[7-(hydroxyamino)-7-oxoheptyl]-1H-1,2,3-triazol-4-yl}phenyl)carbamoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthyl)ethyl]-4-[(tert-butyldimethylsilyl)oxy]-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 1431473-55-0 (4R,6R)-6-[2-((1S,2S,6R,8S,8aR)-8-[((4-{1-[7-(hydroxyamino)-7-oxoheptyl]-1H-1,2,3-triazol-4-yl}benzyl)carbamoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthyl)ethyl]-4-[(tert-butyldimethylsilyl)oxy]-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 1431473-52-7 C₄₁H₆₀N₄O₇Si 
• 1431473-53-8 C₄₂H₆₂N₄O₇Si 
• 1431473-49-2 (1S,3R,7S,8S,8αR)-8-(2-((2R,4R)-4-((tert-butyldimethylchlorosilane)oxy)-6-oxohexahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8α-hexahydronaphthalene-1-yl(4-nitrophenyl)carbonate 
• 1002347-71-8 C₂₅H₃₂⁽²⁾H₆O₅ 
• 1335460-29-1 C₃₁H₄₆⁽²⁾H₆O₅Si 
• 101314-85-6 Carbonic acid (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-(tert-butyl-dimethyl-silanyloxy)-6-oxo-tetrahydro-pyran-2-yl]-ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester phenyl ester 
• 143747-00-6 6(R)-<2-<8(R)-<(2,2-dimethylbutanoyl)oxy>-2(S),6(S)-dimethyl-7(S)-<1(S)-<(tert-butyldimethylsilyl)oxy>benzyl>-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)>ethyl>-4(R)-<(tert-butyldimethylsilyl)oxy>-3,4,5,6-tetrahydro-2H-pyran-2-one 

Relevant academic research and scientific papers

HMG-COA REDUCTASE DEGRADATION INDUCING COMPOUND

The present invention relates HMG-CoA reductase degradation inducing compounds. Specifically, the present invention relates a bifunctional compound in which a HMG-CoA reductase binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention also relates a method for preparing the compounds, and a method for degradation of HMG-CoA reducatase using the compounds, as well as use for prevention or treatment of HMG-CoA reductase related diseases using the compounds.

A compound targeting ubiquitination degradation HMGCR or a pharmaceutically acceptable salt thereof. Preparation method and application

The invention relates to a compound of targeted ubiquitination degradation HMGCR or a pharmaceutically acceptable salt thereof as well as a preparation method and application thereof. The structure is shown in the general formula (I). The compound or the

Hydroxy methyl glutaryl coenzyme A reductase inhibitors

The invention relates to a compound, in particular to an HMG-GoA reductase inhibitor. The HMG-GoA reductase inhibitor is ester formed by naphthol and Cn polyhydroxyalkanoate or Cn olefine acid of the compound in the formula I, wherein n is an integer from six to fourteen. The compound can be effectively used for treating or preventing dyslipidemia, for example, the compound can effectively treat or prevent hypercholesteremia or mixed type hyperlipidemia.

DUAL ACTION INHIBITORS AGAINST HISTONE DEACETYLASES AND 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE

Disclosed herein are novel compounds of formula (I), and uses thereof. The compounds of Formula (I) are inhibitors of histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Also provided are methods of using the

Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme a reductase for cancer treatment

A series of dual-action compounds were designed to target histone deacetylase (HDAC) and 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) by having a hydroxamate group essential for chelation with the zinc ion in the active site of HDAC and the key structural elements of statin for binding with both proteins. In our study, the statin hydroxamic acids prepared by a fused strategy are most promising in cancer treatments. These compounds showed potent inhibitory activities against HDACs and HMGR with IC50 values in the nanomolar range. These compounds also effectively reduced the HMGR activity as well as promoted the acetylations of histone and tubulin in cancer cells, but were not toxic to normal cells.

HYPOCHOLESTEROLEMIC, ANTI-INFLAMMATORY AND ANTIEPILEPTIC NEUROPROTECTIVE COMPOUND

The present invention describes a compound of formula (I) its hydroxy acid form, the pharmaceutically acceptable salts of said hydroxy acid and pharmaceutically acceptable prodrugs and solvates of the compound and of its hydroxy acid form and, in particular, said compound, its hydroxy acid form, salts, etc. for use in the prevention of: neurodegenerative diseases, cognitive impairment, diseases associated with undesired oxidation, age-associated pathological processes and progeria, cardiovascular diseases such as atherosclerosis, atrial fibrillation, dyslipidemia, hypercholesterolemia, hyperlipidemia, and hypertriglyceridemia, inflammation or inflammatory processes, or epilepsy, epileptic seizures and convulsions.

Synthesis of deuterium-labeled simvastatin

This study describes the synthesis of deuterium-labeled simvastatin. The stable isotope-labeled compound was prepared starting from lovastatin in nine steps with 9% overall yield.

Process for Preparing Substantially Pure Simvastatin

This invention relates to an improved process for preparing substantially pure simvastatin (I), chemically known as (1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2-H-pyran-2-yl]ethyl]-3 ,7-dimeth-yl-1,2,3,7,8,8a-Hexahydronaphthalen-1-yl2,2-dimethyl butanoate, which comprises of: a) treating lovastatin (II) with an alkali metal hydroxide in a chosen suitable alcoholic solvent followed by relactonization to obtain the diol lactone intermediate (III) in a single vessel. b) selective silylation of 4-hydroxy group of diol lactone intermediate (III) with a chosen suitable silylating reagent to obtain mono silylated intermediate diol lactone (IV). c) acylation of the mono silylated intermediate (IV) to form silylated simvastatin (V) Or optionally, preparing silylated simvastatin (V) starting from Lovastatin (II) without isolating diol lactone (III) and monosilylated diol lactone (IV) and d) finally, removal of the silyl protecting group on silylated simvastatin (V) followed by purification to provide substantially pure simvastatin (I).

Neuroprotective, hypocholesterolemic and antiepileptic compound

The present invention describes a compound of formula (I) its hydroxy acid form, the pharmaceutically acceptable salts of said hydroxy acid and pharmaceutically acceptable prodrugs and solvates of the compound and of its hydroxy acid form and, in particular, said compound, its hydroxy acid form, salts, etc. for its use in the prevention of: neurodegenerative diseases, cognitive deterioration, diseases associated with undesired oxidation, age-associated pathological processes and progeria, epilepsy, epileptic seizures and convulsions, cardiovascular diseases such as atherosclerosis, atrial fibrillation, dyslipemia, hypercholesterolemia, hyperlipidemia, and hypertriglyceridemia, or fungal or viral infections.

METHOD OF PREPARING STATINS INTERMEDIATES

Provided is a method for preparing a simvastatin intermediate. The method includes hydrolysis of mevinolinic acid as a starting material, lactonization, and protection of a hydroxy group of a lactone ring. Therefore, process steps are reduced and the simvastatin intermediate is produced in high yield.